SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SciClone Pharmaceuticals, Inc
12.86
-0.23 (-1.76%)
Real-time:   11:58AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.84 - 13.14
52 week 6.47 - 13.76
Open 13.06
Vol / Avg. 81,407.00/824,622.00
Mkt cap 627.96M
P/E 22.82
Div/yield     -
EPS 0.56
Shares 49.65M
Beta 1.67
Inst. own 76%
Jun 10, 2016
SciClone Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 SciClone Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 SciClone Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Apr 13, 2016
SciClone Pharmaceuticals Inc at Needham Healthcare Conference
Mar 10, 2016
Q4 2015 SciClone Pharmaceuticals Inc Earnings Call
Mar 10, 2016
Q4 2015 SciClone Pharmaceuticals Inc Earnings Release
Feb 9, 2016
SciClone Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 29.27% 18.74%
Operating margin 29.61% 19.02%
EBITD margin - 19.61%
Return on average assets 24.02% 14.79%
Return on average equity 29.11% 17.59%
Employees 590 -
CDP Score - -

Address

950 Tower Ln Ste 900
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Officers and directors

Jon S. Saxe Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Wilson W. Cheung Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 46
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 51
Bio & Compensation  - Reuters
Robert S. King Ph.D. Senior Vice President - Product Development and Supply Chain
Age: 48
Bio & Compensation  - Reuters
Raymond A Low CPA Vice President - Finance, Controller
Age: 58
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Age: 52
Bio & Compensation  - Reuters
Lan Xie CPA Vice President - Finance, China Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters